Niigata Cancer Center Hospital

Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow‐Up Study of JCOG1302A

ABSTRACT Background Long‐term overall survival (OS) of gastric cancer stratified by the prospectively determined clinical stage remains unclear. Methods This is an ancillary study of JCOG1302A, a prospective observational study that evaluated the accuracy of clinical diagnosis of...

Perioperative Durvalumab for Resectable NSCLC : Updated Outcomes for Japanese Patients in AEGEAN

ABSTRACT In the phase 3 AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved the primary endpoints of event‐free survival (EFS) and pathological complete response (pCR) in patients with resectable NSCLC versus neoadjuvant chemotherapy alone....

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

Abstract Background In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation. Methods Pat...

Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed

Background/Aim: Pembrolizumab combined with pemetrexed is efficacious in older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of <50%. However, treatment-related pneumonitis is concerning, and its impact on clinic...

Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502

Abstract Background Surgery and chemoradiotherapy (CRT) are standard options for clinical stage I esophageal squamous cell carcinoma (ESCC). JCOG0502, a multicenter, non-randomized, parallel-group comparison, demonstrated the non-inferiority of definitive CRT compared with surger...

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

BACKGROUND: Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. He...